Escudo de la República de Colombia
Sistema Nacional de Biliotecas - Repositorio Institucional Universidad Nacional de Colombia Biblioteca Digital - Repositorio Institucional UN Sistema Nacional de Bibliotecas UN

The cost-effectiveness of enzyme replacement therapy (ert) for the infantile form of pompe disease: comparing a high-income country’s approach (england) to that of a middleincome one (colombia)

Castro Jaramillo, Hector Eduardo (2012) The cost-effectiveness of enzyme replacement therapy (ert) for the infantile form of pompe disease: comparing a high-income country’s approach (england) to that of a middleincome one (colombia). Journal of Public Health; Vol. 14, núm. 1 (2012); 143-155 Revista de Salud Pública; Vol. 14, núm. 1 (2012); 143-155 0124-0064 .

Texto completo

[img]
Vista previa
PDF
184kB
[img] Sin Definir
[img] Microsoft Word
14kB
[img] Microsoft Word
269kB
[img] Microsoft Word
266kB
[img]
Vista previa
Imagen (JPEG)
1MB
[img] Microsoft Word
208kB

URL oficial: http://revistas.unal.edu.co/index.php/revsaludpubl...

Resumen

Objectives Determining the cost-effectiveness of enzyme replacement therapy (ERT) for the classical infantile form of Pompe disease (complete acid α-glucosidase defi ciency-related) in two different settings: England and Colombia. Pompe disease is very rare (1:40,000 births incidence). Methods A literature review was made and historic databases searched for National Health Service (NHS) reimbursed costs in England and by health insurers in Colombia; expert opinion was elicited. Two Markov models were constructed for comparing both countries; alive with symptoms and dead were the transition states used. Patients aged ≤ 6 months receiving ERT were assumed to have 75 % survival rate and better health-related quality of life (HR-QoL) compared to those without treatment (0.700 HR- QoL using the EQ-5D scale). Results The incremental cost-effectiveness ratio (ICER) per quality-adjusted life year (QALY) gained was £234,307.7 for England and £109,991 for Colombia. Uncertainty about fi nal HR-QoL with ERT, disease progression and cost from palliative care had the biggest impact on the ICER in both models. If ERT costs were reduced to 10,000 times per dose and HR-QoL was 0.750-0.820 ICER, then £165,000 could be attainable for England and £65,000 for Colombia. Transaction costs per case in Colombia were high. Conclusions ERT was more effective than no ERT in treating infantile Pompe disease, but high levels of uncertainty still remain about survival and progression rates and QoL in the long-run. ICERs were high compared to CE thresholds. Manufacturers’ ERT costs and monopoly had a major impact on fi nal CEA results.

Tipo de documento:Artículo - Article
Palabras clave:evaluación economica en salud, farmacoeconomia, enfermedades huerfanas, enfermedades de alto costo, sistemas de salud, terapia reemplazo enzimatica, Glycogen storage disease type II, Pompe disease, cost and cost analysis, cost- benefi t analysis, quality of life, Economia de salud, Salud Publica, Politicas de salud, Pediatria
Unidad administrativa:Revistas electrónicas UN > Revista de Salud Pública
Código ID:21420
Enviado por : Dirección Nacional de Bibliotecas STECNICO
Enviado el día :27 Junio 2014 12:30
Ultima modificación:18 Agosto 2014 15:34
Ultima modificación:18 Agosto 2014 15:34
Exportar:Clic aquí
Estadísticas:Clic aquí
Compartir:

Solamente administradores del repositorio: página de control del ítem

Vicerrectoría de Investigación: Número uno en investigación
Indexado por:
Indexado por Scholar Google WorldCat DRIVER Registry of Open Access Repositories OpenDOAR Metabiblioteca BDCOL OAIster Red de repositorios latinoamericanos DSpace BASE Open archives La referencia Colombiae Open Access Theses and Dissertations Tesis latinoamericanas CLACSO
Este sitio web se ve mejor en Firefox